- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zim Laboratories Limited — Important, 03-12-2025: Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
03-12-2025 | 01:49 pm
03-12-2025 | 01:49 pm
ZIM Labs received CDSCO approval for its innovative Naproxen + Esomeprazole FDC capsules, boosting its pain management & gastro-protective portfolio. A commercial supply agreement is signed, targeting India launch in FY26-27. This reinforces ZIM's strategy in differentiated generics.
No comments yet. Be the first to comment!